[go: up one dir, main page]

GT200900123A - Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace - Google Patents

Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace

Info

Publication number
GT200900123A
GT200900123A GT200900123A GT200900123A GT200900123A GT 200900123 A GT200900123 A GT 200900123A GT 200900123 A GT200900123 A GT 200900123A GT 200900123 A GT200900123 A GT 200900123A GT 200900123 A GT200900123 A GT 200900123A
Authority
GT
Guatemala
Prior art keywords
compounds
methods
inhibit
interaction
link molecule
Prior art date
Application number
GT200900123A
Other languages
English (en)
Inventor
Alfredo C Castro
Edward B Holson
Brian T Hopkins
Nii O Koney
Daniel A Snyder
Thomas T Tibbitts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900123A publication Critical patent/GT200900123A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EL PRESENTE INVENTO SE RELACIONA CON LOS COMPUESTOS HETEROCÍCLICOS QUE ENLAZAN LAS PROTEÍNAS BCL Y BLOQUEAN LA FUNCIÓN BCL. OTRO DE LOS ASPECTOS DEL PRESENTE INVENTO SE RELACIONA CON LAS COMPOSICIONES QUE COMPRENDEN UN COMPUESTO HETEROCÍCLICO DEL INVENTO. EL PRESENTE INVENTO PRESENTA MÉTODOS PARA TRATAR Y MODULAR LOS DESÓRDENES RELACIONADOS CON LA HIPERPROLIFERACIÓN, TAL COMO EL CÁNCER.
GT200900123A 2006-11-15 2009-05-12 Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace GT200900123A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/600,332 US7842815B2 (en) 2004-06-17 2006-11-15 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

Publications (1)

Publication Number Publication Date
GT200900123A true GT200900123A (es) 2011-09-02

Family

ID=39064388

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900123A GT200900123A (es) 2006-11-15 2009-05-12 Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace

Country Status (20)

Country Link
US (2) US7842815B2 (es)
EP (1) EP2094673B1 (es)
JP (2) JP2010510214A (es)
KR (1) KR101530721B1 (es)
CN (1) CN101583606B (es)
AU (1) AU2007319848B2 (es)
BR (1) BRPI0718606A2 (es)
CA (1) CA2669596C (es)
EC (1) ECSP099398A (es)
ES (1) ES2537762T3 (es)
GT (1) GT200900123A (es)
IL (1) IL198597A (es)
MA (1) MA31067B1 (es)
MX (1) MX2009005184A (es)
MY (1) MY156754A (es)
NO (1) NO20092306L (es)
NZ (1) NZ577243A (es)
RU (1) RU2449996C2 (es)
TN (1) TN2009000182A1 (es)
WO (1) WO2008060569A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
CN101980718A (zh) * 2008-02-08 2011-02-23 爱勒让治疗公司 治疗性的拟肽大环化合物
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
CA2852468A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
JP6141327B2 (ja) 2012-02-06 2017-06-07 ディスカヴァーエックス コーポレイション タンパク質存在量の測定による細胞内結合事象の検出
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
SG10201606775YA (en) 2012-02-15 2016-10-28 Aileron Therapeutics Inc Peptidomimetic macrocycles
CN103656642A (zh) * 2012-08-31 2014-03-26 中国科学院上海生命科学研究院 预防和治疗结直肠癌的方法和试剂
EP2961738B1 (en) 2012-11-14 2019-12-25 CJ CheilJedang Corporation Production of salts of 4-hydroxybutyrate using biobased raw materials
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
EP3669881B1 (en) 2014-01-28 2022-03-30 Buck Institute for Research on Aging Compositions for use in the treatment of senescence-assiocated eye disease and disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
IL295472B2 (en) 2016-03-28 2024-10-01 Presage Biosciences Inc Pharmaceutical combinations for the treatment of cancer
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
TWI863657B (zh) * 2017-04-05 2024-11-21 哈佛大學校長及研究員協會 巨環化合物及其用途
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN113453679B (zh) 2018-12-20 2025-07-08 C4医药公司 靶向蛋白降解
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
WO2022008464A1 (en) 2020-07-06 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55133364A (en) 1979-04-03 1980-10-17 Mitsubishi Petrochem Co Ltd Preparation of isoxazolidine derivative
DE3643012A1 (de) 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
KR100188801B1 (ko) 1990-05-18 1999-06-01 엥겔하르트 라피체 이속사졸-4카복스아미드 및 하이드록시알킬리덴 시아노아세트아미드 및 이들 화합물을 함유하는 약제학적 조성물
US5294617A (en) * 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
DK0623615T3 (da) * 1993-05-01 1999-12-13 Merck Patent Gmbh Adhæsionsreceptor-antagonister
FI962184L (fi) 1993-11-24 1996-05-23 Du Pont Merck Pharma Uusia isoksatsoliini- ja isoksatsolifibrinogeenireseptoriantagonisteja
DE69503769T2 (de) 1994-03-09 1998-12-03 Pfizer Inc., New York, N.Y. Isoxazoline verbindung zur hemmung tnf-freigabe
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE19539638A1 (de) 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6221865B1 (en) * 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
DE69718194T2 (de) 1996-08-16 2003-10-16 Bristol-Myers Squibb Pharma Co., Wilmington Amidinophenyl-pyrrolidine, -pyrroline und -isoxazolidine und ihre derivate
WO1998016830A2 (en) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Droplet assay system
AU7371998A (en) 1997-05-07 1998-11-27 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
WO2001016115A1 (en) 1999-09-01 2001-03-08 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolidines
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
EP1474121B1 (en) 2001-05-30 2010-07-21 The Regents Of The University Of Michigan Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
KR101195351B1 (ko) 2004-06-17 2012-10-29 인피니티 디스커버리, 인코포레이티드 Ｂｃｌ 단백질과 결합 파트너와의 상호작용을 억제하는화합물 및 방법
US20060020004A1 (en) * 2004-06-17 2006-01-26 Infinity Pharmaceuticals, Inc. Isoxazolidine compounds for treatment of bacterial infections
TWI403320B (zh) * 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法

Also Published As

Publication number Publication date
KR101530721B1 (ko) 2015-06-22
US20070161690A1 (en) 2007-07-12
IL198597A (en) 2014-03-31
US20110160259A1 (en) 2011-06-30
WO2008060569A1 (en) 2008-05-22
HK1130057A1 (en) 2009-12-18
CA2669596C (en) 2014-09-30
RU2009121808A (ru) 2010-12-20
US20080306127A9 (en) 2008-12-11
ES2537762T3 (es) 2015-06-11
ECSP099398A (es) 2009-07-31
TN2009000182A1 (en) 2010-10-18
EP2094673B1 (en) 2015-04-08
US7842815B2 (en) 2010-11-30
NO20092306L (no) 2009-08-17
IL198597A0 (en) 2010-02-17
AU2007319848A1 (en) 2008-05-22
US8461191B2 (en) 2013-06-11
AU2007319848B2 (en) 2012-05-03
NZ577243A (en) 2011-12-22
BRPI0718606A2 (pt) 2013-12-17
CA2669596A1 (en) 2008-05-22
MY156754A (en) 2016-03-31
MA31067B1 (fr) 2010-01-04
KR20090082284A (ko) 2009-07-29
JP2014055156A (ja) 2014-03-27
JP2010510214A (ja) 2010-04-02
CN101583606A (zh) 2009-11-18
EP2094673A1 (en) 2009-09-02
RU2449996C2 (ru) 2012-05-10
CN101583606B (zh) 2015-04-08
MX2009005184A (es) 2009-10-12

Similar Documents

Publication Publication Date Title
GT200900123A (es) Compuestos y metodos para inhibir la interacción de las proteinas bcl con molécula de enlace
ECSP088607A (es) Compuestos y métodos para inhibir la interacción de las proteínas bcl con las parejas de unión
GT200600328A (es) Derivados de isoquinolona sustituidos con piperidinilo
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
GT200600327A (es) Ciclohexilaminoisoquinolona
GT200900183A (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina
GT201000376A (es) Compuestos organicos
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
HN2006018410A (es) Nuevos derivados del fluoreno, composiciones que los contienen y utilizacion
UY30843A1 (es) Derivados de isoquinolona sustituidos con ciloalquilamina
CL2007002424A1 (es) Compuestos derivados de isoxazolidina; composicion farmaceutica que comprende a dicho compuesto, util para el tratamiento de trastornos asociados con hiperproliferacion como cancer.
GT200800198A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1.
ECSP088103A (es) Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
ECSP10010705A (es) Isoquinolinas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
GT200800102A (es) Compuestos y metodos para inhibir la interaccion de proteinas bcl con moleculas de enlace
CO6341625A2 (es) Derivados de indol como agentes anticáncer
PA8667201A1 (es) Nuevos compuestos farmaceuticos
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CO6321288A2 (es) Sales de compuestos inhibidores de vih